PF-04634817
Unknown / undisclosed
Evidence outlook · program status
Discontinued, after a negative readout
PF-04634817 was Pfizer's oral CCR2/CCR5 chemokine receptor antagonist, taken to phase 2 in diabetic nephropathy and diabetic macular edema. This Pfizer-authored report of the diabetic nephropathy phase 2 states that clinical development was discontinued because the albuminuria reduction was too modest; the drug had also failed non-inferiority against ranibizumab in diabetic macular edema. The paper gives no date for the decision. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01712061 NCT01712061 · Diabetic Nephropathy The trial randomized 226 participants to double-blinded PF-04634817 or matching placebo, providing a reasonably controlled comparison. Its primary endpoint was the surrogate biomarker UACR rather than a clinical kidney outcome, and the primary comparison was not statistically significant, with a 95% confidence interval that included no difference. Registry: NCT01712061 | 2 | Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline and Week 12) 2014-09 | Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline and Week 12): PF-04634817 200 mg/150 mg 13.27 percent (%) (95% CI 3.14 to 24.62) | Placebo 5.02 percent (%) (95% CI -7.9 to 18.7) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.